Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma has received a notice from Cosette Pharmaceuticals purporting to terminate their Scheme Implementation Deed (SID) due to unmet conditions. However, Mayne Pharma disputes the validity of this termination, arguing that Cosette’s failure to meet its obligations under the SID contributed to the unmet conditions. The company has reserved its rights regarding Cosette’s non-compliance, potentially impacting the future of their collaboration and market positioning.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to offer safer and more accessible medicines. It is a leader in dermatology and women’s health in the United States and provides contract development and manufacturing services globally. With a 40-year history of innovation, Mayne Pharma has developed new oral drug delivery systems that have been successfully commercialized worldwide.
Average Trading Volume: 535,857
Technical Sentiment Signal: Sell
Current Market Cap: A$260.8M
Learn more about MYX stock on TipRanks’ Stock Analysis page.